When happens becomes tough, for some corporate venture capital companies it is typical to strive for the hills.
Today it is a story that reappears amid the crisis of COVID-19. Global corporate venture capital transactions fell from 580 in April / May 2019 to 486 over the same period this year, according to Global corporate enterprise,
Nevertheless, institutional venture capital transactions are also declining, as PitchBook expects a decline in transaction volume over the next few quarters, as well as a decline in valuation.
It is still unknown how this will develop this time, but I believe that corporate venture capital (CVC) will not only remain, but will become an important part of the innovation ecosystem in the future.
I know it Merck Global Health Innovation Fund (MGHIF) remains fully committed to the “establishment” of the enterprise. Now more than ever, innovation in the healthcare sector is vital. Secondly, we understand that many of the most successful companies today were funded in times of uncertainty. In fact, in order to put our money where we speak, we recently completed two splits, three subsequent investments and two new deals in 2020 – all this since the advent of COVID. We intend to increase this pace in the future and in 2020.
That was not easy. It’s hard to take risks when you cannot go out into the world, meet with the founders and work hard as we did in the past. But this is possible if you make some kind of your own innovations and configure a well-functioning system for virtual CVC.
Here’s how we did it.